Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this randomized clinical trial, minoxidil at 5 mg was not found to be superior to 2.5 mg for treating male androgenetic alopecia over 24 weeks, though the higher dose more frequently caused side effects like pre-tibial edema and dizziness.

This study found that oral cyclosporine therapy was more effective than betamethasone mini-pulse therapy for treating alopecia areata, with a better patient-reported outcome on hair regrowth, despite a higher incidence of mild, reversible adverse effects in the cyclosporine group.

This study found that an exosome formulation with plant extracts significantly increased hair regrowth in men with male pattern alopecia compared to a placebo, without notable adverse effects.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

In this study, researchers found that autologous platelet-rich plasma injections significantly improved hair density and patient satisfaction in both male and female patients with androgenetic alopecia, with no major side effects reported.

In this randomized trial, oral supplementation with Serenoa repens, pumpkin seed extracts, and cysteine significantly improved the clinical effectiveness of topical 5% minoxidil lotion for treating androgenic alopecia in men and women compared to minoxidil alone, with both treatments being well tolerated.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.

In this phase I/II clinical trial, placenta-derived mesenchymal stem cell exosome therapy significantly improved hair density and diameter, and reduced hair loss in patients with androgenetic alopecia, though further large-scale studies are needed to confirm these results and investigate the underlying molecular mechanisms.

In this clinical trial, 16 women with frontal fibrosing alopecia experienced significant improvements in hair density, vellus hair count, and quality of life after monthly intralesional dutasteride treatments, though larger and longer-term studies are needed to confirm these findings.

This study is designed to explore how circadian rhythms are affected by obesity and mental health conditions, such as schizophrenia and bipolar disorder, using biological and lifestyle data from independently living adults.

This study found that combining platelet-rich plasma with topical minoxidil led to the greatest increase in terminal hair density at 32 weeks, while low-dose oral minoxidil was more effective at reducing vellus hair density in men with androgenetic alopecia.

The study found that combining platelet-rich plasma with topical minoxidil significantly improved terminal hair density in androgenetic alopecia patients, while low-dose oral minoxidil was more effective at reducing vellus hair density.

In this randomized trial, lupus patients taking daily 200 μg selenium supplements for eight weeks showed significant improvements in metabolic markers like CRP, ESR, MDA, and GPX, as well as reduced clinical symptoms such as arthritis and alopecia, compared to those receiving a placebo.

This study surveyed individuals seeking estrogen-based gender-affirming hormone therapy, revealing that improving life satisfaction and femininity are top treatment goals, and highlighting the need for trials aligned with community priorities.

This randomized controlled trial investigated the impact of a placebo on non-vellus hair count in individuals with androgenetic alopecia, a common form of hair loss affecting both men and women, but results were not reported.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This randomized control trial reported that patients with alopecia areata typically have lower serum Vitamin D levels, and treatment with topical vitamin D3 analogue calcipotriol led to significant hair regrowth in 71% of participants over six months.

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

In this clinical trial, oral consumption of a persimmon leaf extract-containing complex significantly increased hair density and thickness over 24 weeks compared to a placebo, although improvements in hair gloss were not statistically significant.

This study found that combining fractional ablative erbium YAG laser with minoxidil led to slightly better dermoscopy scores than minoxidil alone in male patients with moderate to severe androgenetic alopecia, although no significant difference was observed in photography scores between the two groups.

In this triple-blind, randomized clinical trial, researchers found that oral Amla syrup significantly increased the anagen-to-telogen hair ratio and satisfaction levels in women with Female Androgenetic Alopecia compared to placebo, suggesting its potential benefit for treating androgenic hair loss.

This study found that photobiomodulation may accelerate hair regrowth one month after chemotherapy in breast cancer patients, but no significant differences were observed at two and three months post-therapy.

This randomized clinical trial found that oral contraceptives containing desogestrel were associated with more adverse effects on serum lipids and blood pressure compared to those containing drospirenone in patients with polycystic ovary syndrome.

This study demonstrated that a daily oral supplement of 1000 mg Kera-Diet® improved hair and nail conditions in women experiencing acute telogen effluvium and brittle nail syndrome over three months.

This study found that the YH0618 decoction reduced chemotherapy-induced nail discoloration, alopecia, skin hyperpigmentation, and fatigue in cancer patients who completed chemotherapy.

This clinical trial found that Sandalore® 1% significantly reduced hair shedding and increased hair volume and anagen hair follicles in women with telogen effluvium compared to placebo.

This clinical trial found that topical application of Sandalore® 1% significantly reduced hair shedding and increased hair volume in women with telogen effluvium compared to placebo.